ctDNA dynamics and mechanisms of acquired resistance in patients treated with osimertinib with or without bevacizumab from the randomised phase II ETOP-BOOSTER trial.

Ross Andrew Soo Urania Dafni Ji-Youn Han Byoung Chul Cho Ernest Nadal Chong Ming Yeo Enric Carcereny Javier De Castro Carpeño Maria Angeles Sala Linda Coate Mariano Provencio Pulla Christian Britschgi Patrick Vagenknecht Georgia Dimopoulou Roswitha Kammler Stephen P Finn Solange Peters Rolf A Stahel

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

The differential effect of treatment by smoking was not explained by TP53 mutation or other molecular alterations examined. Molecular mechanisms of acquired resistance were detected but no novel molecular alterations were identified in the combination arm.

Keyphrases

phase ii
clinical trial
open label
placebo controlled
double blind
phase iii
study protocol
small cell lung cancer
single molecule
epidermal growth factor receptor
randomized controlled trial
smoking cessation
advanced non small cell lung cancer
circulating tumor
metastatic colorectal cancer